Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM‐878

AIMS: Recently, we identified a novel orexin 2 (OX(2)) receptor antagonist, SDM‐878 (2‐(3‐(2‐(1H‐pyrazol‐1‐yl)nicotinoyl)‐3,8‐diazabicyclo[3.2.1]octan‐8‐yl)‐3‐methoxyisonicotinonitrile). The purpose of the present study is to characterize the in vitro and in vivo pharmacological effects of SDM‐878....

Descripción completa

Detalles Bibliográficos
Autores principales: Maehara, Shunsuke, Yuge, Natsuko, Higashi, Chika, Ota, Takumi, Furukawa, Junji, Takeuchi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722660/
https://www.ncbi.nlm.nih.gov/pubmed/32337858
http://dx.doi.org/10.1002/npr2.12105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722660/
https://www.ncbi.nlm.nih.gov/pubmed/32337858
http://dx.doi.org/10.1002/npr2.12105

Ejemplares similares